Cargando…
GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma
BACKGROUND: Meningiomas are the most common primary intracranial tumours. They are classified as grade I, II, and III based on their histopathological features. While most meningiomas can be managed by surgery alone, adjuvant treatment may be required in case of recurrent, or high-grade tumours. To...
Autores principales: | Negroni, Caterina, Hilton, David A., Ercolano, Emanuela, Adams, Claire L., Kurian, Kathreena M., Baiz, Daniele, Hanemann, C.Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452696/ https://www.ncbi.nlm.nih.gov/pubmed/32810829 http://dx.doi.org/10.1016/j.ebiom.2020.102941 |
Ejemplares similares
-
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas
por: Sofela, Agbolahan A., et al.
Publicado: (2021) -
Constitutive activation of the EGFR–STAT1 axis increases proliferation of meningioma tumor cells
por: Ferluga, Sara, et al.
Publicado: (2020) -
A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours
por: Adams, Claire L., et al.
Publicado: (2020) -
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma
por: Lyons Rimmer, Jade, et al.
Publicado: (2020) -
Genomic landscape of high-grade meningiomas
por: Bi, Wenya Linda, et al.
Publicado: (2017)